We serve Chemical Name:8-Iodoquinazolin-4(3H)-one CAS:77150-36-8 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:8-Iodoquinazolin-4(3H)-one
CAS.NO:77150-36-8
Synonyms:8-iodo-1H-quinazolin-4-one
Molecular Formula:C8H5IN2O
Molecular Weight:272.04300
HS Code:
Physical and Chemical Properties:
Melting point:N/A
Boiling point:N/A
Density:N/A
Index of Refraction:
PSA:46.01000
Exact Mass:271.94500
LogP:1.94000
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:
Contact us for information like 8-iodo-1H-quinazolin-4-one chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,8-iodo-1H-quinazolin-4-one physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,8-iodo-1H-quinazolin-4-one Use and application,8-iodo-1H-quinazolin-4-one technical grade,usp/ep/jp grade.
Related News: Compared with existing Imbruvica therapies, where patients take the BTK inhibitor daily—potentially for years—until their disease progresses, the new Venclexta combo caps treatment at about 14 months. That could offer a new option for “probably younger patients with CLL that prefer more flexible, treatment-free intervals,” said Craig Tendler, M.D., vice president of oncology clinical development and global medical affairs at J&J’s Janssen unit, during an interview. 8-Iodoquinazolin-4(3H)-one manufacturer Health officials said it remained unclear where he had developed the disease. 8-Iodoquinazolin-4(3H)-one supplier Health officials said it remained unclear where he had developed the disease. 8-Iodoquinazolin-4(3H)-one vendor Active pharmaceutical ingredients directly impact disease. 8-Iodoquinazolin-4(3H)-one factory Compared with existing Imbruvica therapies, where patients take the BTK inhibitor daily—potentially for years—until their disease progresses, the new Venclexta combo caps treatment at about 14 months. That could offer a new option for “probably younger patients with CLL that prefer more flexible, treatment-free intervals,” said Craig Tendler, M.D., vice president of oncology clinical development and global medical affairs at J&J’s Janssen unit, during an interview.
